| Wang, Xiaoxia |
NCT06145893: A Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behçet's Disease |
|
|
| Recruiting | 3 | 162 | RoW | Hemay005, Mufemilast, Phosphodiesterase 4 (PDE4) inhibitors, Placebo | Ganzhou Hemay Pharmaceutical Co., Ltd | Behçet's Disease | 11/24 | 03/25 | | |
| Recruiting | 2/3 | 240 | Europe, Canada, Japan, US, RoW | EFG PH20 SC, PBO | argenx, argenx BV | Active Idiopathic Inflammatory Myopathy, Myositis, Dermatomyositis, Polymyositis, Immune-Mediated Necrotizing Myopathy, Antisynthetase Syndrome | 12/26 | 02/27 | | |
NCT04830644: A Study to Evaluate the Efficacy and Safety of Iguratimod Compared to Placebo in Patients With Active Primary Sjogren's Syndrome. |
|
|
| Recruiting | 2 | 144 | RoW | Iguratimod, Placebo | Jiangsu Simcere Pharmaceutical Co., Ltd. | Primary Sjögren Syndrome | 04/22 | 06/22 | | |
NCT06250062: A Clinical Study of JS005 in Patients With Ankylosing Spondylitis |
|
|
| Recruiting | 2 | 261 | RoW | Recombinant humanized IL-17A Monoclonal Antibody（JS005）, Placebo（JS005） | Shanghai Junshi Bioscience Co., Ltd., Sponsor GmbH | Ankylosing Spondylitis | 02/25 | 10/25 | | |
NCT05688696: Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Systemic Lupus Erythematosus |
|
|
| Recruiting | 2 | 186 | RoW | Orelabrutinib (Low Dose), Orelabrutinib (High Dose), Orelabrutinib Placebo | Beijing InnoCare Pharma Tech Co., Ltd. | Systemic Lupus Erythematosus, SLE | 08/25 | 05/26 | | |
NCT05247203: Telitacicept Study in Chinese Subjects With Systemic Lupus Erythematosus |
|
|
| Completed | 1 | 92 | RoW | Telitacicept, RC18, standard therapy | RemeGen Co., Ltd. | Systemic Lupus Erythematosus | 10/23 | 11/23 | | |
NCT02946528: Urgent-start Peritoneal Dialysis in ESRD Patients：A Multi-center Study |
|
|
| Completed | N/A | 116 | RoW | urgent-start peritoneal dialysis catheter, central venous catheter | RenJi Hospital, Ruijin Hospital, Xin Hua Hospital, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Changhai Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai Tong Ren Hospital, Shanghai Jiading District Central Hospital, Shanghai Songjiang District Central Hospital, The Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine, Shanghai Punan Hospital | End-Stage Renal Disease | 11/21 | 11/21 | | |
| Xu, Bing he |
NCT06142552: Phase 3 Clinical Project of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion Protein |
|
|
| Recruiting | 3 | 120 | RoW | FRSW117, Recombinant human coagulation factor Ⅷ-Fc fusion protein for injection | Jiangsu Gensciences lnc. | Severe Hemophilia A | 01/26 | 09/26 | | |
BELIEVE-01, NCT05234684: A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With MCD Subtype Diffuse Large B-cell Lymphoma |
|
|
| Recruiting | 3 | 150 | RoW | Orelabrutinib + R-CHOP, ICP-022+ R-CHOP, Placebo + R-CHOP | Beijing InnoCare Pharma Tech Co., Ltd. | Diffuse Large B Cell Lymphoma (DLBCL) | 07/24 | 12/25 | | |
NCT04578613: ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL |
|
|
| Recruiting | 3 | 218 | RoW | ICP-022, Chlorambucil, Rituximab | Beijing InnoCare Pharma Tech Co., Ltd. | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 12/24 | 06/25 | | |
LOTIS 5, NCT04384484 / 2020-000241-14: Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma |
|
|
| Active, not recruiting | 3 | 440 | Europe, Canada, Japan, US, RoW | Loncastuximab Tesirine, Zynlonta, ADCT-402, Rituximab, Gemcitabine, Oxaliplatin | ADC Therapeutics S.A., ADC Therapeutics SA | Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | 06/25 | 06/28 | | |
|
|
|
NCT06004856: Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Chronic Primary Immune Thrombocytopenia |
|
|
| Recruiting | 3 | 195 | RoW | Orelabrutinib, Placebo | Beijing InnoCare Pharma Tech Co., Ltd. | Chronic Primary Immune Thrombocytopenia (ITP) | 12/25 | 04/26 | | |
SYMPHONY-1, NCT04224493 / 2019-003333-42: A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma. |
|
|
| Recruiting | 3 | 612 | Europe, Canada, US, RoW | Tazemetostat, EPZ-6438, IPN60200, Placebo oral tablet, Lenalidomide, Rituximab | Epizyme, Inc. | Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma | 03/26 | 03/29 | | |
|
|
|
|
|
|
|
ICP-CL-01203, NCT06378138: ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma |
|
|
| Recruiting | 2/3 | 226 | RoW | ICP-248, Orelabrutinib | Beijing InnoCare Pharma Tech Co., Ltd. | Hematologic Malignancies | 11/30 | 07/31 | | |
NCT04324879: A Study of TQ-B3525 in the Treatment of Relapsed / Refractory Follicular Lymphoma (FL) |
|
|
| Recruiting | 2 | 80 | RoW | TQ-B3525 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Relapsed / Refractory Follicular Lymphoma | 12/22 | 12/22 | | |
NCT06158412: All-trans Retinoic Acid in Combination With a KPD Regimen for the Treatment of Refractory/Relapsed Multiple Myeloma |
|
|
| Recruiting | 2 | 25 | RoW | All-trans Retinoic Acid in combination with the KPD Regimen | The First Affiliated Hospital of Xiamen University | Multiple Myeloma in Relapse, Multiple Myeloma, Refractory | 12/25 | 12/25 | | |
NCT06151106: Chidamide and Duvalisibon for the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma |
|
|
| Recruiting | 2 | 33 | RoW | Chidamide combined with Duvillisib | The First Affiliated Hospital of Xiamen University, Fujian Cancer Hospital, Zhangzhou Affiliated Hospital of Fujian Medical University, Dongguan People's Hospital, Huizhou Municipal Central Hospital, The First Affiliated Hospital with Nanjing Medical University, Sun Yat-sen University, Shanxi Province Cancer Hospital | Peripheral T Cell Lymphoma, Relapsed Peripheral T-Cell Lymphoma, Refractory T-Cell Lymphoma | 12/24 | 12/25 | | |
NCT06158386: Chidamide Combined With Linperlisibon for the Treatment of Refractory/Relapsed Follicular Lymphoma |
|
|
| Recruiting | 2 | 33 | RoW | Chidamide combined with Linperlisib | The First Affiliated Hospital of Xiamen University, Fujian Provincial Hospital, Fujian Cancer Hospital, Zhangzhou Affiliated Hospital of Fujian Medical University, Jieyang People's Hospital, Dongguan People's Hospital, Huizhou Municipal Central Hospital, The First Affiliated Hospital with Nanjing Medical University, Sun Yat-sen University, Shanxi Province Cancer Hospital | Follicular Lymphoma, Refractory B-Cell Lymphoma, Relapsed Non-Hodgkin Lymphoma | 12/24 | 12/25 | | |
NCT06151080: Lenalidomide Combined With G-CHOP in the Treatment of Newly Diagnosed DLBCL With FL |
|
|
| Recruiting | 2 | 38 | RoW | Lenalidomide combined with G-CHOP (LO CHOP) | The First Affiliated Hospital of Xiamen University, The First Affiliated Hospital with Nanjing Medical University, Sun Yat-sen University, Jiangxi Provincial Cancer Hospital, Fujian Cancer Hospital | DLBCL - Diffuse Large B Cell Lymphoma, Follicular Lymphoma | 08/25 | 12/26 | | |
| Recruiting | 2 | 52 | RoW | Azacitidine in combination with R-CHOP | The First Affiliated Hospital of Xiamen University, Jiangsu Provincial People's Hospital, Sun Yat-sen University, Chinese Academy of Medical Sciences, Shanxi Province Cancer Hospital | DLBCL - Diffuse Large B Cell Lymphoma, TP53 | 05/25 | 05/25 | | |
NCT05305859: Venetoclax Combining Chidamide and Azacitidine (VCA) in the Treatment of R/R AML |
|
|
| Recruiting | 2 | 30 | RoW | venetoclax combining chidamide and azacitidine (VCA), VCA | The First Affiliated Hospital of Xiamen University, Fujian Provincial Hospital, Fujian Cancer Hospital, Zhangzhou manicipal hospital of Fujian Province, Jieyang People's Hospital, Dongguan People's Hospital, Huizhou Municipal Central Hospital | Leukemia, Myeloid, Acute, Relapsed Adult AML, Refractory Leukemia | 01/26 | 06/27 | | |
NCT06553352: Zanubrutinib in Combination With Obinutuzumab (ZO) for Newly Diagnosed Follicular Lymphoma |
|
|
| Recruiting | 2 | 39 | RoW | Zanubrutinib combined with Obinutuzumab, Zanubrutinib combined with Obinutuzumab (ZO) | The First Affiliated Hospital of Xiamen University, Shanxi Provincial Cancer Hospital, The First Hospital of Jilin University, Fujian Cancer Hospital, Jiangxi Provincial Cancer Hospital, The Second Affiliated Hospital of Dalian Medical University, Sun Yat-sen University, Huazhong University of Science and Technology | Follicular Lymphoma, Newly Diagnosed | 04/26 | 08/27 | | |
NCT04849351: Clinical Study of HMPL-689 for Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma |
|
|
| Recruiting | 2 | 185 | RoW | HMPL-689, Phosphatidylinositol 3-kinase-δ inhibitor | Hutchison Medipharma Limited | Marginal Zone Lymphoma, Follicular Lymphoma | 04/24 | 12/24 | | |
NCT06581640: Chimeric Antigen Receptor Modified T Cells Targeting BCMA for the Treatment of Relapsed/Refractory Multiple Myeloma |
|
|
| Recruiting | 2 | 5 | RoW | CAR-T treatment | The First Affiliated Hospital of Xiamen University | Multiple Myeloma, Relapsed/Refractory | 12/28 | 12/28 | | |
NCT05603884: VCA Regimen Followed by D-MAG Regimen on the Treatment of Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) |
|
|
| Recruiting | 2 | 66 | RoW | Venetoclax Combining Chidamide and Azacitidine (VCA) regimen followed by dicitabine combined with liposome mitoxantrone, cytarabine, and G-CSF (D-MAG) regimen | The First Affiliated Hospital of Xiamen University, Chipscreen Biosciences, Ltd., CSPC Pharmaceutical Group Limited, Fujian Provincial Hospital, Fujian Cancer Hospital, Zhangzhou manicipal hospital of Fujian Province, Jieyang People's Hospital, Huizhou Municipal Central Hospital | Leukemia, Myeloid, Acute, AML Stage, Adult | 12/26 | 12/26 | | |
NCT04835870: Zanubrutinib Plus R-CHOP for Patients With Newly Diagnosed Untreated Non-GCB DLBCL |
|
|
| Recruiting | 2 | 78 | RoW | Zanubrutinib, BTK inhibitors, Rituximab, MabThera, Cyclophosphamide, CTX, Doxorubicin, ADM, Vincristine, VCR, Prednisone, Prednisonum | The First Affiliated Hospital of Soochow University | Non-GCB/ABC Diffuse Large B-Cell Lymphoma | 10/25 | 10/25 | | |
NCT04202003: A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of TJ011133 as Monotherapy and in Combination With Azacitidine (AZA) in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) |
|
|
| Completed | 1/2 | 105 | RoW | TJ011133 | TJ Biopharma Co., Ltd. | Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes(MDS) | 12/23 | 12/23 | | |
|
|
NCT06106841: TQB3909 Tablets in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (MCL) |
|
|
| Recruiting | 1/2 | 39 | RoW | 400mg of TQB3909 tablets, 600mg of TQB3909 tablets | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Mantle Cell Lymphoma | 12/24 | 12/24 | | |
| Recruiting | 1 | 191 | RoW | ICP-248, ICP-248+Orelabrutinib | Beijing InnoCare Pharma Tech Co., Ltd. | Hematological Malignancies | 08/25 | 10/26 | | |
NCT06651866: Dose-escalation Study of D-CMG Regimen for the Treatment of Elderly Newly Diagnosed AML Patients |
|
|
| Recruiting | 1 | 18 | RoW | D-CMG | The First Affiliated Hospital of Xiamen University | Acute Myeloid Leukemia | 12/26 | 06/27 | | |
NCT06737523: Chiglitazar Sodium Combined With Venetoclax and Azacitidine (CVA) for the Treatment of R/R AML |
|
|
| Recruiting | 1 | 30 | RoW | CVA | The First Affiliated Hospital of Xiamen University | Acute Myeloid Leukemia, Relapse, Refractory AML | 12/25 | 12/26 | | |
NCT05979792: Clinical Study of CD7 CAR-T Cell Injection in the Treatment of Patients With Relapsed or Refractory CD7-positive Peripheral T Cell Lymphoma |
|
|
| Not yet recruiting | 1 | 35 | RoW | CAR-T Therapy | Zhao Weili | Peripheral T Cell Lymphoma | 08/25 | 12/25 | | |
| Completed | N/A | 1006 | RoW | | Takeda | Lymphoma | 07/24 | 07/24 | | |
NCT06151119: 68Ga-FAPI PET/CT Imaging for Diagnosis, Grading, and Efficacy Evaluation of Myelofibrosis. |
|
|
| Recruiting | N/A | 90 | RoW | 68Ga FAPI PET/CT | The First Affiliated Hospital of Xiamen University | Primary Myelofibrosis | 10/24 | 06/25 | | |
NCT06478472: Prospective Clinical Study of Orelabrutinib in Combination With Rituximab (OR) for Primary Marginal Zone Lymphoma (MZL) That Failed or Not Suitable for Local Therapy |
|
|
| Recruiting | N/A | 36 | RoW | Orelabrutinib in combination with rituximab | The First Affiliated Hospital of Xiamen University, The First Hospital of Jilin University, Fujian Cancer Hospital, Guangdong Provincial People's Hospital, Nanfang Hospital, Southern Medical University, The Second Affiliated Hospital of Dalian Medical University, Jiangxi Provincial Cancer Hospital, Wuhan Union Hospital, China, Shanxi Provincial Cancer Hospital, Chinese PLA General Hospital | Marginal Zone Lymphoma | 06/27 | 06/27 | | |
NCT04837222: A Study of Brentuximab Vedotin in Adults With CD30-positive Lymphoma |
|
|
| Active, not recruiting | N/A | 1000 | RoW | No Intervention | Takeda | Lymphoma | 06/26 | 06/26 | | |
| Zheng, Jie |
| Completed | 3 | 1281 | Europe, Canada, Japan, US, RoW | Mirikizumab, LY3074828, Placebo | Eli Lilly and Company | Ulcerative Colitis | 01/21 | 05/24 | | |
|
|
|
|
| Recruiting | 2/3 | 240 | Europe, Canada, Japan, US, RoW | EFG PH20 SC, PBO | argenx, argenx BV | Active Idiopathic Inflammatory Myopathy, Myositis, Dermatomyositis, Polymyositis, Immune-Mediated Necrotizing Myopathy, Antisynthetase Syndrome | 12/26 | 02/27 | | |
NCT05702268: Pharmacodynamic Blood Characteristics of ICP-332 in Patients With Moderate to Severe Atopic Dermatitis |
|
|
| Recruiting | 2 | 75 | RoW | ICP-332, ICP-332 Placebo | Beijing InnoCare Pharma Tech Co., Ltd. | Moderate to Severe Atopic Dermatitis | 07/23 | 12/23 | | |
| Completed | 2 | 456 | Europe, Japan, US, RoW | Enpatoran low dose, M5049, Enpatoran medium dose, Enpatoran high dose, Placebo | EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany | Systemic Lupus Erythematosus | 11/24 | 11/24 | | |
|
|
NCT03217617: SCID-X1 Gene Therapy Via Intravenous Lentiviral (Ivlv-X1) Injection |
|
|
| Recruiting | 1/2 | 10 | RoW | Direct intravenous injection of ivlv-X1 lentiviral vector | Shenzhen Geno-Immune Medical Institute | SCID, X-Linked | 12/26 | 12/27 | | |
NCT03645460: Gene Therapy for ADA-SCID Using an Improved Lentiviral Vector (Ivlv-ADA) |
|
|
| Recruiting | N/A | 10 | RoW | Direct intravenous injection of ivlv-ADA lentiviral vector | Shenzhen Geno-Immune Medical Institute | Adenosine DeAminase Severe Combined ImmunoDeficiency (ADA-SCID) | 12/26 | 12/27 | | |
NCT06167668: The Influence of Internet + Combined Family Empowerment Management Mode on Treatment Compliance of PATIENTS With CKD |
|
|
| Recruiting | N/A | 100 | RoW | the routine chronic disease management mode, the family-centered family enabling health management mode | Shanxi Medical University | Internet, Chronic Kidney Disease | 07/24 | 11/24 | | |
| Recruiting | N/A | 10000 | RoW | Installation or registration of smartphone application | Chinese Alliance Against Lung Cancer | Solitary Pulmonary Nodule | 10/25 | 10/25 | | |
| Yang, Linhua |
NCT04845399: Phase III Expansion Trial for Determining the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A |
|
|
| Completed | 3 | 101 | RoW | Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection | Zhengzhou Gensciences Inc, Jiangsu Gensciences lnc. | Hemophilia A | 06/21 | 06/21 | | |
NCT05203679: Evaluation of the Safety and Efficacy of Hemophilia B Gene Therapy Drug |
|
|
| Active, not recruiting | 3 | 32 | RoW | Single dose intravenous injection of BBM-H901 | Shanghai Belief-Delivery BioMed Co., Ltd | Hemophilia B | 04/24 | 06/28 | | |
NCT04233346: The Study for CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL Who Failed Prior TKIs or With T315I Mutation |
|
|
| Active, not recruiting | 2 | 90 | RoW | Ponatinib, Iclusig, AP24534 | Otsuka Beijing Research Institute | Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia | 07/22 | 12/25 | | |
| Wang, Lihua |
NCT04263922: Huaiqihuang Granule in the Treatment of Primary Glomerulonephritis of Stage CKD3 |
|
|
| Recruiting | 4 | 466 | RoW | Huaiqihuang granules, B12000050755, Valsartan capsule, H20030638 | The First Affiliated Hospital of Dalian Medical University, Huazhong University of Science and Technology, LinkDoc Technology (Beijing) Co. Ltd. | Renal Insufficiency, Chronic | 10/25 | 03/26 | | |
SHINY, NCT06157502: Shuxuening Injection in the Treatment With Intravenous Thrombolysis in Patients With Ischemic Stroke |
|
|
| Recruiting | 3 | 1380 | RoW | Shuxuening Injection, Placebo | Beijing Tiantan Hospital | Ischemic Stroke, Acute | 06/25 | 12/26 | | |
NCT05975268: A Clinical Study to Evaluate the Efficacy and Safety of Subcutaneous JS005 Injection in the Treatment of Adults With Moderate to Severe Chronic Plaque Psoriasis |
|
|
| Active, not recruiting | 3 | 747 | RoW | JS005 (recombinant humanized monoclonal antibody against IL-17A) | Shanghai Junshi Bioscience Co., Ltd. | Moderate to Severe Chronic Plaque Psoriasis | 08/25 | 10/25 | | |
NCT06319846: Tirofiban for Patients With intraCranial Artery Stenosis and High-risk Acute Non-disabling Cerebrovascular Events(CHANCE-4） |
|
|
| Recruiting | 3 | 4674 | RoW | Tirofiban, Placebo | Beijing Tiantan Hospital | Ischemic Stroke, Acute, TIA, Symptomatic Intracranial Artery Stenosis | 10/25 | 12/26 | | |
| Recruiting | 3 | 189 | RoW | Roflumilast Cream 0.3%, Zoryve, Vehicle cream | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Plaque Psoriasis | 06/25 | 07/25 | | |
NCT06631170: Efficacy and Safety of Roflumilast Cream in Subjects with Atopic Dermatitis |
|
|
| Recruiting | 3 | 351 | RoW | Roflumilast Cream 0.15%, Vehicle cream | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Atopic Dermatitis (AD) | 08/25 | 08/25 | | |
NCT06413654: A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD) |
|
|
| Recruiting | 2/3 | 132 | RoW | B001, Placebo | Shanghai Jiaolian Drug Research and Development Co., Ltd, Shanghai Pharmaceuticals Holding Co., Ltd | Neuromyelitis Optica Spectrum Disorders | 10/27 | 02/29 | | |
NCT06109818: Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ICP-488 in Patients With Moderate to Severe Plaque Psoriasis |
|
|
| Recruiting | 2 | 129 | RoW | ICP-488 Tablets, ICP-488 Placebo | Beijing InnoCare Pharma Tech Co., Ltd. | Moderate to Severe Plaque Psoriasis | 10/24 | 11/24 | | |
NCT05593575: Efficacy and Safety of SPH3127 Tablets on Treating the Diabetic Kidney Disease |
|
|
| Recruiting | 2 | 320 | RoW | SPH3127+SPH3127matching placebo+valsartan matching placebo, SPH3127+valsartan matching placebo, SPH3127 matching placebo+valsartan | Shanghai Pharmaceuticals Holding Co., Ltd | Diabetic Kidney Disease | 06/25 | 06/25 | | |
| Suspended | 2 | 279 | Europe, US, RoW | zetomipzomib, KZR-616, placebo, matching placebo | Kezar Life Sciences, Inc. | Lupus Nephritis | 05/26 | 07/26 | | |
| Recruiting | N/A | 366 | Canada, RoW | | The George Institute, Peking University Institute of Nephrology | IgA Nephropathy, ESRD, Glomerulonephritis, Kidney Diseases | 07/27 | 07/27 | | |
NCT05454397: A Study on the Status of Nutritional Risk Screening and Nutritional Therapy in Neurology Hospitalized Stroke Patients |
|
|
| Recruiting | N/A | 2000 | RoW | Observational study, no intervention | Nanfang Hospital of Southern Medical University, First Affiliated Hospital of Fujian Medical University, Yantai Yuhuangding Hospital, The First Hospital of Jilin University, Qilu Hospital of Shandong University, ZHEJIANG PROVINCE XIAOSHAN HOSPITAL, The First People's Hospital of Wenling, Ganzhou People's Hospital, Affiliated Hospital of Jining Medical hospital, Henan Provincial People's Hospital, Zhongda Hospital Southeast University, The Second Affiliated Hospital of Harbin Medical University, The First people's Hospital of Kunshan, The 2nd Affiliated Hospital of Wenzhou Medical University, THE FIRST PEOPLE'S HOSPITAL OF JIASHAN, The First Affiliated Hospital of Xi'an Jiaotong University Medical College, Fujian Province Zhangzhou Hospital, People's Hospital of Chongqing, Nanjing Zijin Hospital, Hangzhou Red Cross Hospital, Wenzhou Hospital of Chinese Medicine, Kaifeng Central Hospital, First Affiliated Hospital of Guangxi Medical University, Zhongshan Hospital of Xiamen University, Xi'an Encephalopathy of Traditional Chinese Medicine Hospital, 903 Hospital of the Chinese People's Liberation Army Joint Logistics and Security Forces, Xiangya Hospital of Central South University, Second Affiliated Hospital of Suzhou University, Tongji Hospital, The Affiliated Hospital o fQingdao University, The First Affiliated Hospital of Anhui Medical University, Yancheng Third People's Hospital, Linyi People's Hospital, Dongfang Hospital of Beijing University of Chinese Medicine, Affiliated Hospital of Qingdao University | Acute Stroke | 10/22 | 10/23 | | |
| Hou, Ruigang |
| Completed | 1 | 24 | RoW | PJ009, Glucagon-like Peptide-2 (GLP-2) analogue, Placebo | Chongqing Peg-Bio Biopharm Co., Ltd. | Short Bowel Syndrome | 05/23 | 05/23 | | |
| Feng, Yi |
QLG2069-AMS-301, NCT05822713: A Comparison of the Efficacy of Amisulpride and Placebo in the Prevention of PONV in Patients at Moderate-to-high Risk of PONV. |
|
|
| Not yet recruiting | 3 | 516 | NA | Amisulpride, Amisulpride Placebo | Qilu Pharmaceutical (Hainan) Co., Ltd. | PONV | 08/23 | 12/23 | | |
| Active, not recruiting | 3 | 90 | Europe, Canada, US, RoW | Pimicotinib(ABSK021), Placebo | Abbisko Therapeutics Co, Ltd | Tenosynovial Giant Cell Tumor, Pigmented Villonodular Synovitis, Giant Cell Tumor of Tendon Sheath | 05/26 | 06/28 | | |
NCT03761576: The Role of Cognitive Function and Electroencephalography on Acute and Chronic Pain After Surgery |
|
|
| Enrolling by invitation | N/A | 100 | RoW | | Yi Feng, MD | Acute Pain, Chronic Pain, Thoracic Surgery, Electroencephalography, Brain Mechanism | 03/21 | 10/23 | | |
NCT04822870: Comparison of Ultrasound-guided Quadratus Lumborum Block and Iliohypogastric/Ilioinguinal Nerve Block for Postoperative Pain Management in Patients Undergoing Cesarean Section |
|
|
| Enrolling by invitation | N/A | 87 | RoW | quadratus lumborum block, iliohypogastric/ilioinguinal nerve block, epidural analgesia | Peking University People's Hospital | Quadratus Lumborum Block, Iliohypogastric/Ilioinguinal Nerve Block, Cesarean Section | 05/21 | 05/21 | | |
NCT04652427: Application of Dexmedetomidine Hydrochloride Injection in Anesthesia for Patients Without Tracheal Intubation |
|
|
| Recruiting | N/A | 240 | RoW | Dexmedetomidine Hydrochloride 0.1 MG/ML, sedation, 0.9% Sodium Chloride Injection, saline solution | Peking University People's Hospital | Sedation Complication | 08/21 | 08/22 | | |
NCT04544605: Special Chinese Medicine Out-patient Programme for Discharged COVID-19 Patients |
|
|
| Recruiting | N/A | 150 | RoW | Individualized-Chinese herbal medicine | Hong Kong Baptist University, The University of Hong Kong, Chinese University of Hong Kong | Post COVID-19 | 09/21 | 12/21 | | |
NCT05304923: Supraglottic Jet Oxygenation and Ventilation for Gastrointestinal Endoscopy at High-altitude |
|
|
| Recruiting | N/A | 72 | RoW | Supraglottic jet oxygenation and ventilation, Nasal cannula oxygen supply | Peking University People's Hospital, Tibet Autonomous Region People's Hospital | Hypoxia, High Altitude | 08/22 | 08/22 | | |
NCT05434403: Transauricular Vagus Nerve Stimulation in the Treatment of Chemotherapy-induced Peripheral Neuropathy |
|
|
| Enrolling by invitation | N/A | 26 | RoW | Vagus nerve stimulation, sham vagus nerve stimulation | Peking University People's Hospital | CIPN, Chemotherapy-induced Peripheral Neuropathy | 08/22 | 11/22 | | |
HRQoL, NCT03926858: Patient-reported Outcomes of Postsurgical Pain and Health Related Quality of Life |
|
|
| Completed | N/A | 2000 | RoW | | Peking University People's Hospital | Post Surgical Pain | 05/23 | 05/23 | | |
NCT05474287: SJOV vs. HFNO for Hypoxia During Procedural Sedation at High Altitudes |
|
|
| Recruiting | N/A | 72 | RoW | SJOV, HFNO | Peking University People's Hospital, Tibet Autonomous Region People's Hospital | Hypoxia, High Altitude | 02/23 | 02/23 | | |
NCT06503432: The Effects of Programmed Death-ligand 1 on Postoperative Pain for Lung Cancer Patients |
|
|
| Recruiting | N/A | 100 | RoW | | Peking University People's Hospital | Lung Cancer, Postoperative Pain | 02/25 | 03/25 | | |
NCT04923399: Transcriptome Sequencing Analysis of Whole Blood From Patients With Trigeminal Neuralgia |
|
|
| Not yet recruiting | N/A | 20 | NA | | Peking University People's Hospital | Trigeminal Neuralgia, Blood, Plasma, Cerebrospinal Fluid | 06/23 | 06/23 | | |
| Hao, Min |
| Active, not recruiting | 3 | 502 | Europe, Canada, Japan, US, RoW | tisotumab vedotin, TIVDAK, topotecan, vinorelbine, gemcitabine, irinotecan, pemetrexed | Seagen Inc., Genmab | Cervical Cancer | 07/23 | 08/25 | | |
TQB2450-II-08, NCT04574284: A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Subjects With Advanced Endometrial Cancer |
|
|
| Recruiting | 2 | 196 | RoW | TQB2450, Anlotinib | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Endometrial Cancer | 12/21 | 04/22 | | |
| Shen, Jingnan |
| Active, not recruiting | 3 | 90 | Europe, Canada, US, RoW | Pimicotinib(ABSK021), Placebo | Abbisko Therapeutics Co, Ltd | Tenosynovial Giant Cell Tumor, Pigmented Villonodular Synovitis, Giant Cell Tumor of Tendon Sheath | 05/26 | 06/28 | | |
ALMB-0168 002, NCT06416358: A Study to Evaluate the Efficacy of ALMB-0168 in Solid Tumor Patients With Bone Metastatic Whose Prior Standard Treatment Have Failed |
|
|
| Not yet recruiting | 2 | 144 | NA | ALMB-0168 | AlaMab Therapeutics (Shanghai) Inc. | Advanced Solid Tumors With Bone Only Metastasis | 06/26 | 12/26 | | |
| Recruiting | 2 | 170 | RoW | HS-20093 | Hansoh BioMedical R&D Company | Osteosarcoma, Sarcoma | 12/25 | 12/27 | | |
| Not yet recruiting | 1/2 | 238 | NA | ALMB-0168 | AlaMab Therapeutics (Shanghai) Inc., CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Osteosarcoma | 11/23 | 05/24 | | |
NCT05944224: A Study to Efficacy and Safety of SPH4336 Monotherapy or in Combination With Cadonilimab in Patients With Advanced Solid Tumors. |
|
|
| Recruiting | 1/2 | 63 | RoW | SPH4336, Cadonilimab | Shanghai Pharmaceuticals Holding Co., Ltd | Advanced Solid Tumors | 05/25 | 12/25 | | |
NCT04192344: A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-021 in Patients With Advanced Solid Tumor |
|
|
| Recruiting | 1 | 85 | US, RoW | ABSK021 | Abbisko Therapeutics Co, Ltd | Neoplasms, Tenosynovial Giant Cell Tumor | 12/25 | 12/25 | | |
| Ma, Yanping |
TE-ITP, NCT05583838: A Randomized Trial Comparing Optimized rhTPO Treatment With Eltrombopag Treatment in Pre-treated ITP Pts |
|
|
| Completed | 4 | 157 | RoW | rhTPO, Recombinant human thrombopoietin, TPIAO, Eltrombopag, Eltrombopag olamine | Institute of Hematology & Blood Diseases Hospital, China, The Second Hospital of Hebei Medical University, Xijing Hospital, The Affiliated Hospital of Inner Mongolia Medical University, The Second Affiliated Hospital of Kunming Medical University, Second Affiliated Hospital of Guangzhou Medical University, Shaanxi Provincial People's Hospital, Henan Cancer Hospital, North China University of Science and Technology Affiliated Hospital, The Second Affiliated Hospital of Dalian Medical University, Second Hospital of Shanxi Medical University, The Second Affiliated Hospital of Harbin Medical University, Shenyang Sunshine Pharmaceutical Co., LTD., First Affiliated Hospital of Xinjiang Medical University, People's Hospital of Xinjiang Uygur Autonomous Region, Kashgar 1st People's Hospital, Xi'an Central Hospital, Beijing Public Health Foundation, Yuyao People's Hospital of Zhejiang Province | Previously Treated Primary Immune Thrombocytopenia | 02/24 | 07/24 | | |
NCT05236621: A Study of the Efficacy and Safety of Pomalidomide Capsules Combined With Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma |
|
|
| Active, not recruiting | 3 | 85 | RoW | Pomalidomide, Dexamethasone | Qilu Pharmaceutical Co., Ltd. | Multiple Myeloma, Recurrent or Refractory | 06/22 | 12/23 | | |
NCT06142552: Phase 3 Clinical Project of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion Protein |
|
|
| Recruiting | 3 | 120 | RoW | FRSW117, Recombinant human coagulation factor Ⅷ-Fc fusion protein for injection | Jiangsu Gensciences lnc. | Severe Hemophilia A | 01/26 | 09/26 | | |
| Yuan, Lili |
NCT05379491: Application of Linaclotide Capsule in Bowel Preparation for Patients at High Risk of Inadequate Bowel Preparation |
|
|
| Completed | N/A | 720 | RoW | 3 L PEG + linaclotide, 3 L PEG + placebo | Zhiguo Liu | Colonoscopy | 06/23 | 07/23 | | |
| Zhang, Linzhong |
NCT05518929: Hypoxia During Gastroenterological Endoscope Procedures Sedated With Ciprofol In Overweight Or Obesity Patients |
|
|
| Completed | 4 | 1090 | RoW | Ciprofol, Propofol | RenJi Hospital, Zhejiang Tumor Hospital, Beijing Hospital, Second Hospital of Shanxi Medical University, Dalian Municipal Friendship Hospital | Gastric Ulcer, Gastric Cancer, Gastrointestinal Polyp | 08/23 | 08/23 | | |
| Recruiting | N/A | 1250 | RoW | EEG(Electroencephalogram) change | Air Force Military Medical University, China | Aging, Postoperative Cognitive Dysfunction, EEG With Periodic Abnormalities | 03/23 | 04/23 | | |
PROTECT, NCT05401058: Low-dose Droperidol for Prevention of Postoperative Delirium in Elderly Patients After Non-cardiac Surgery |
|
|
| Recruiting | N/A | 2968 | RoW | Droperidol Injection, D, Saline, S | RenJi Hospital | Digestive System Disease, Urologic Diseases, Gynecological Disease, Orthopedic Surgery | 12/24 | 12/24 | | |
| Zhu, Yikun |
EFFECT, NCT05902078: Eldecalcitol and Calcitriol in Postmenopausal Women With Low Bone Mineral Density or Mild Osteoporosis |
|
|
| Recruiting | 4 | 300 | RoW | Eldecalcitol capsules, Edirol, Calcitriol capsules, Haidewei | Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Chugai Pharma China Co., Ltd. | Low Bone Mineral Density, Postmenopausal Osteoporosis | 06/25 | 12/25 | | |
NCT05352516 / 2022-002188-31: A Study to Evaluate the Efficacy and Safety of HLX14 vs. Denosumab Prolia® in Postmenopausal Women With Osteoporosis at High Risk of Fracture |
|
|
| Completed | 3 | 514 | RoW | HLX14, Prolia® | Shanghai Henlius Biotech, Shanghai Henlius Biotech, Inc. | Postmenopausal | 12/23 | 07/24 | | |
NCT05866029: Study of the Key Techniques of Prevention and Treatment of Osteoporotic Refracture |
|
|
| Recruiting | N/A | 2478 | RoW | Denosumab, Teriparatide | Peking Union Medical College Hospital | Osteoporotic Fractures | 09/26 | 09/26 | | |
| Guan, Kunping |
NCT05638269: A Multicentre Study on Features of the Gut Microbiota of Patients With Critical Chronic Diseases in China |
|
|
| Recruiting | N/A | 12000 | RoW | no intervention | Zhujiang Hospital, National Natural Science Foundation of China | Essential Hypertension, Liver Cancer, Nasopharyngeal Cancer, Pancreatic Cancer, Lung Cancer, Chronic Kidney Diseases, Acute Coronary Syndrome, Epilepsy, Gastric Cancer, Primary Aldosteronism, Subclinical hypothyroïdism | 12/24 | 12/25 | | |
| Chen, Jianfang |
NCT05651061: A Phase I of SS109 in Hemophilia A or and B With Inhibitors |
|
|
| Completed | 1 | 27 | RoW | SS109 | Jiangsu Gensciences lnc. | Hemophilia A With Inhibitor, Hemophilia B With Inhibitor, Factor VII Deficiency | 03/23 | 08/23 | | |
| Feng, Wenli |
NCT06477237: Study of Efficacy and Safety of HB0017 in Patients With Moderate to Severe Plaque Psoriasis |
|
|
| Recruiting | 3 | 400 | RoW | HB0017 Q4W, HB0017 Q8W, placebo | Huabo Biopharm Co., Ltd. | Psoriasis | 08/24 | 12/25 | | |
NCT06587685: A Study to Assess the Efficacy and Safety of PG-011 Gel in Adolescents and Adults With Atopic Dermatitis |
|
|
| Recruiting | 3 | 472 | RoW | PG-011Gel, PG-011Gel 3%, Vehicle, placebo | Prime Gene Therapeutics Co., Ltd. | Atopic Dermatitis | 12/24 | 01/26 | | |
NCT05975268: A Clinical Study to Evaluate the Efficacy and Safety of Subcutaneous JS005 Injection in the Treatment of Adults With Moderate to Severe Chronic Plaque Psoriasis |
|
|
| Active, not recruiting | 3 | 747 | RoW | JS005 (recombinant humanized monoclonal antibody against IL-17A) | Shanghai Junshi Bioscience Co., Ltd. | Moderate to Severe Chronic Plaque Psoriasis | 08/25 | 10/25 | | |
NCT05702268: Pharmacodynamic Blood Characteristics of ICP-332 in Patients With Moderate to Severe Atopic Dermatitis |
|
|
| Recruiting | 2 | 75 | RoW | ICP-332, ICP-332 Placebo | Beijing InnoCare Pharma Tech Co., Ltd. | Moderate to Severe Atopic Dermatitis | 07/23 | 12/23 | | |
NCT06109818: Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ICP-488 in Patients With Moderate to Severe Plaque Psoriasis |
|
|
| Recruiting | 2 | 129 | RoW | ICP-488 Tablets, ICP-488 Placebo | Beijing InnoCare Pharma Tech Co., Ltd. | Moderate to Severe Plaque Psoriasis | 10/24 | 11/24 | | |
| Wang, Bei |
NCT06103825: A Twelve-week, Double-blind, Placebo-controlled, Randomized, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Solriamfetol in the Treatment of Excessive Daytime Sleepiness (EDS) in Patients With Obstructive Sleep Apnea (OSA) |
|
|
| Recruiting | 3 | 204 | RoW | Solriamfetol, Placebo | Ignis Therapeutics (Suzhou) Limited | Excessive Daytime Sleepiness Associated With Obstructive Sleep Apnea | 09/24 | 10/24 | | |
NCT06010693: A Study of Daridorexant in Chinese Patients With Insomnia Disorder |
|
|
| Completed | 3 | 206 | RoW | Daridorexant, Placebo | Jiangsu Simcere Pharmaceutical Co., Ltd. | Insomnia Disorder | 04/24 | 05/24 | | |
| Hou, Gehui |
| Active, not recruiting | 3 | 90 | Europe, Canada, US, RoW | Pimicotinib(ABSK021), Placebo | Abbisko Therapeutics Co, Ltd | Tenosynovial Giant Cell Tumor, Pigmented Villonodular Synovitis, Giant Cell Tumor of Tendon Sheath | 05/26 | 06/28 | | |
